Akeso and Summit Therapeutics have shared the full data from the HARMONi-6 trial of PD-1xVEGF bispecific ivonescimab as a ...
Susan Galbraith, Ph.D., AZ’s oncology R&D chief, attributed Datroway’s strong efficacy to its ADC construct, specifically its ...
A new preliminary study published in Nature suggests that COVID-19 vaccines might actually boost the immune system to make ...
Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder ...
Patients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were twice ...
Medpage Today on MSN
First-Line Bladder Cancer Trial Makes the Case for HER2 Screening
The first iteration of HER2-targeted drugs showed limited activity in bladder cancer, but the rise of antibody-drug ...
Groundbreaking research reveals mRNA COVID-19 vaccines may significantly boost cancer immunotherapy success. Patients ...
Farber-co-led phase 3 trial shows that periodic ctDNA screening after surgery can help guide a decision to begin adjuvant ...
Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo –– ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback